All Oncology News

The FDA has placed a partial clinical hold on trials of selinexor (KPT-330), which is being explored in several tumor types.

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.

The FDA has approved the CDK 4/6 inhibitor ribociclib (Kisqali) for use in combination with an aromatase inhibitor as a frontline treatment for postmenopausal women with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer.

Michael F. Press, MD, PhD, discusses issues with the ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization testing.

Hope Rugo, MD, highlights the latest efforts to improve outcomes in triple-negative breast cancer.

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.

Vassiliki A. Papadimitrakopoulou, MD, discusses recent developments with immunotherapy in non­-small cell lung cancer and the continued significance of EGFR and ALK inhibitors in the field.

Brian F. Chapin, MD, discusses the importance of active surveillance in patients with prostate cancer at a low risk of developing metastases and the benefits of surgery and radiation as active treatment methods for patients with locally advanced disease.

Imatinib continued to show dramatic overall survival benefits after nearly 11 years of follow-up despite crossover for patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase.

A supplemental biologics license application for pembrolizumab (Keytruda) for previously treated patients with advanced microsatellite instability-high cancer remains under review by the FDA.

John C. Araujo, MD, PhD, discusses targeted therapies, current and emerging, for patients with bone-metastatic castration-resistant prostate cancer.

Eric Jonasch, MD, speaks on the evolving choices for patients with renal cell carcinoma in the first- and second-line settings, as well as the remaining challenges in the field.

Dmitriy Zamarin, MD, PhD, discusses the current state of immunotherapy in gynecologic cancers and necessary next steps for advancement in these diseases.

Daniel Petrylak, MD, discusses the significance of genetics in the future of prostate cancer care and highlights emerging treatments and challenges in the field.

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.

Charles Drake, MD, PhD, discusses pairing immunotherapy with chemotherapy, the efficacy of current immunotherapy agents, and the future use of immunotherapy in the treatment of genitourinary cancers.

Ramesh K. Ramanathan, MD, discusses emerging agents and the hurdles oncologists are facing in the field of pancreatic cancer.

Toni Choueiri, MD, discusses a study of the MET inhibitor savolitinib in papillary renal cell cancer as well as other exciting findings in kidney cancer.

Scientists at the Sidney Kimmel Cancer Center at Thomas Jefferson University have developed a non-invasive technique to detect the presence of prostate cancer cells in patients' urine.

Researchers at the Sidney Kimmel Cancer Center at Thomas Jefferson University discover that isomiRs (small non-coding RNA molecules produced in a cell) are powerful enough to classify accurately samples that can belong to 32-different types of cancer.

FLT3 targeted agents are emerging in the treatment of acute myeloid leukemia, and which specific agent will be most effective is highly dependent on whether a patient has been previously treated.

The addition of ublituximab to ibrutinib significantly improved objective response rates compared with ibrutinib alone for patients with previously treated high-risk chronic lymphocytic leukemia.

The FDA has lifted its clinical hold on several phase I trials of the antibody-drug conjugate vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia.

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.

Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.

Arturo Loaiza-Bonilla, MD, discusses the potential role of BRAF and CTNNB1 mutations in the survival difference between colorectal cancer patients with left- and right-sided tumors.

Denosumab (Xgeva) demonstrated noninferiority to zoledronic acid (Zometa) at delaying the time to the first skeletal-related event in patients with multiple myeloma, according to the full results of the phase III 482 study presented at the 16th International Myeloma Workshop in New Delhi.

Tanios Bekaii-Saab, MD, discusses optimal sequencing with regorafenib (Stivarga) and TAS-102 (Lonsurf) in relapsed patients with metastatic colorectal cancer and combination regimens on the rise in the setting.

Jonathan Strosberg, MD, discusses the overall findings of the NETTER-1 trial and the quality of life analysis in patients with midgut neuroendocrine tumors.